A Small Company With A Partnering Goal
Nuformix (LSE:NFX) does not aim to take its lead drug candidate all the way to market on its own. Instead, its stated plan is to generate enough data on NXP002, an inhaled treatment being developed for lung fibrosis, to attract a development or licensing partner. That raises a practical question for a company of its size: how is it paying for the work, and how long can its resources last while it pursues a deal?
What Nuformix Does
Nuformix is a pharmaceutical development company whose shares are listed on the Main Market of the London Stock Exchange under the code NFX. Its lead programme, NXP002, is being developed for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, serious chronic lung diseases in which scar tissue builds up. The candidate has received Orphan Drug designation from the European Medicines Agency, in May 2025, and from the US Food and Drug Administration, confirmed in March 2026. The data package also includes earlier studies in human lung tissue. The company also has an early-stage preclinical pipeline in fibrosis and oncology. Dr Dan Gooding is executive director.
Funding And Board Changes
The company's half-year report, published on 28 May 2026 and covering the six months to 31 March 2026, set out how recent work has been financed. Nuformix raised £228,081 through an open offer in November 2025, issuing 114.05 million shares at 0.2p, followed by a £1,000,000 placing in March 2026 of 500 million shares at the same price. At 31 March, it reported cash of £930,283 and net Assets of £1,636,439. The loss for the half year narrowed to £346,577 from £376,668, and the loss per share was 0.02p, compared with 0.03p. The directors said cashflow forecasts through December 2027 supported operating for at least 12 months from approval of the accounts.
On 25 August 2026, the company announced that Tim Metcalfe would become non-executive chairman from 1 September 2026, succeeding Dr Julian Gilbert, who stepped down for personal reasons and remains available as a consultant. Mr Metcalfe has more than 30 years of corporate finance and advisory experience, including as joint chief executive of Zeus Capital, and chairs Equipmake Holdings. In announcing his appointment, he indicated that his focus would be on creating Shareholder value through the NXP002 programme. No later announcements had been published at the time of writing.
What The Money Has Bought
On 19 August 2026, Nuformix reported results from an inhaled pharmacokinetic and target engagement study funded by the March placing. The company said NXP002 had been formulated and nebulised successfully across a broad range of concentrations, achieving dose-related lung exposure at levels consistent with expected activity, and reducing alpha-smooth muscle actin, a marker associated with activated myofibroblasts. Dr Gooding said the findings "provide an important bridge" between earlier human lung tissue data and exposures achievable by inhalation. The company planned to share results with prospective partners at the European Respiratory Society Congress in September and to progress towards non-GLP dose-range-finding studies.
Risks To Consider
All work remains preclinical, and animal data do not ensure results in people. A licensing deal is an objective, not a certainty, and its timing and terms cannot be predicted. Potential partners will also compare NXP002 with other fibrosis programmes. With cash below £1 million at the half-year, further studies may require more funding, and the low share price means new Capital can significantly dilute existing holders.
Conclusion
Nuformix is funding its partnering push for NXP002 through small, low-priced share placings, most recently the £1.0 million placing in March 2026, and has used that money for inhalation studies designed to interest licensees. A new chairman with Capital Markets experience joins as the company seeks to convert data into a commercial agreement.
_11_18_2026_09_42_19_750506.jpg)
_11_18_2026_09_43_10_583784.jpg)




Please wait processing your request...